JP2010505867A - ピラゾール化合物 - Google Patents
ピラゾール化合物 Download PDFInfo
- Publication number
- JP2010505867A JP2010505867A JP2009531560A JP2009531560A JP2010505867A JP 2010505867 A JP2010505867 A JP 2010505867A JP 2009531560 A JP2009531560 A JP 2009531560A JP 2009531560 A JP2009531560 A JP 2009531560A JP 2010505867 A JP2010505867 A JP 2010505867A
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CI/C(/I)=C(\*)/[N+]C1C(Cl)=CC(C2CC2)=CC1 Chemical compound CI/C(/I)=C(\*)/[N+]C1C(Cl)=CC(C2CC2)=CC1 0.000 description 3
- WASMFMVCQONSGZ-LTOWZTDGSA-N C/C(/C(C(NC(C1CC1)=O)=O)=N)=C(\c([s]1)ccc1Br)/Nc(c(Cl)c1)ccc1Cl Chemical compound C/C(/C(C(NC(C1CC1)=O)=O)=N)=C(\c([s]1)ccc1Br)/Nc(c(Cl)c1)ccc1Cl WASMFMVCQONSGZ-LTOWZTDGSA-N 0.000 description 1
- ZOTNYFZPTGCOKD-RIEDUCEQSA-N CC(C)(C(NC(C(/C(/C)=C(/c(cc1)ccc1Cl)\Nc(c(Cl)c1)ccc1Cl)=N)=O)=O)N(C)C Chemical compound CC(C)(C(NC(C(/C(/C)=C(/c(cc1)ccc1Cl)\Nc(c(Cl)c1)ccc1Cl)=N)=O)=O)N(C)C ZOTNYFZPTGCOKD-RIEDUCEQSA-N 0.000 description 1
- CWGPJEWLCBNHJQ-UHFFFAOYSA-N CCOC(C(C(C)C(c(cc1)ccc1Cl)=O)=O)=O Chemical compound CCOC(C(C(C)C(c(cc1)ccc1Cl)=O)=O)=O CWGPJEWLCBNHJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
- C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84874206P | 2006-10-02 | 2006-10-02 | |
PCT/US2007/080199 WO2008060771A2 (fr) | 2006-10-02 | 2007-10-02 | Pyrazoles |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010505867A true JP2010505867A (ja) | 2010-02-25 |
Family
ID=39402347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009531560A Pending JP2010505867A (ja) | 2006-10-02 | 2007-10-02 | ピラゾール化合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090042864A2 (fr) |
EP (1) | EP2084135A4 (fr) |
JP (1) | JP2010505867A (fr) |
KR (1) | KR20090107015A (fr) |
CN (1) | CN101528706A (fr) |
AU (1) | AU2007319648A1 (fr) |
CA (1) | CA2664880A1 (fr) |
TW (1) | TWI339205B (fr) |
WO (1) | WO2008060771A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020500916A (ja) * | 2016-12-12 | 2020-01-16 | ベットーレ リミテッド ライアビリティー カンパニーVettore, Llc | Mct4の複素環阻害剤 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008062480A2 (fr) * | 2006-11-24 | 2008-05-29 | Ind-Swift Laboratories Limited | Procédé amélioré de préparation du rimonabant |
WO2009097995A1 (fr) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation |
CN101585810B (zh) * | 2008-05-23 | 2011-12-14 | 华东理工大学 | 一种5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酸酯的制备方法 |
CN104844514B (zh) * | 2015-05-21 | 2017-11-10 | 山东大学 | 二芳基吡唑类化合物及其制备方法与应用 |
CN104873499B (zh) * | 2015-06-11 | 2017-10-17 | 中国医学科学院医药生物技术研究所 | 一种上调Runx2 转录活性的化合物在防治骨质疏松中的应用 |
ES2894919T3 (es) | 2015-06-12 | 2022-02-16 | Vettore Llc | Inhibidores de MCT4 para el tratamiento de enfermedades |
KR101974414B1 (ko) * | 2017-09-12 | 2019-05-02 | 주식회사 티에스디라이프사이언스 | 1h-피라졸-3-아마이드계 화합물 유도체를 포함하는 섬유증 예방 또는 치료용 조성물 |
CN109608415B (zh) * | 2019-01-21 | 2020-12-01 | 暨南大学 | 噻唑甲酰胺类化合物及其合成和应用 |
WO2024036243A2 (fr) * | 2022-08-10 | 2024-02-15 | Vettore, LLC | Sels d'inhibiteurs hétérocycliques du transporteur 4 de monocarboxylate pour le traitement d'une maladie |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92508A0 (en) * | 1988-12-08 | 1990-08-31 | Ciba Geigy Ag | Novel alpha-cyano-beta-oxopropionamides |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US6620804B2 (en) * | 1996-06-03 | 2003-09-16 | Purdue Research Foundation | Selenophene anti-tumor agents |
AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
US6306891B1 (en) * | 1998-06-03 | 2001-10-23 | Merck & Co., Inc. | HIV integrase inhibitors |
WO2005037199A2 (fr) * | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide |
ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
JP5199087B2 (ja) * | 2005-07-29 | 2013-05-15 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | ペプチドデホルミラーゼ阻害剤 |
US7803799B2 (en) * | 2006-07-07 | 2010-09-28 | National Health Research Institutes | Selenophene compounds |
-
2007
- 2007-09-29 TW TW096136524A patent/TWI339205B/zh active
- 2007-10-02 KR KR1020097009171A patent/KR20090107015A/ko not_active Application Discontinuation
- 2007-10-02 US US11/866,233 patent/US20090042864A2/en not_active Abandoned
- 2007-10-02 EP EP07868353A patent/EP2084135A4/fr not_active Withdrawn
- 2007-10-02 CA CA002664880A patent/CA2664880A1/fr not_active Abandoned
- 2007-10-02 AU AU2007319648A patent/AU2007319648A1/en not_active Abandoned
- 2007-10-02 CN CNA200780036890XA patent/CN101528706A/zh active Pending
- 2007-10-02 WO PCT/US2007/080199 patent/WO2008060771A2/fr active Application Filing
- 2007-10-02 JP JP2009531560A patent/JP2010505867A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020500916A (ja) * | 2016-12-12 | 2020-01-16 | ベットーレ リミテッド ライアビリティー カンパニーVettore, Llc | Mct4の複素環阻害剤 |
JP7123929B2 (ja) | 2016-12-12 | 2022-08-23 | ベットーレ リミテッド ライアビリティー カンパニー | Mct4の複素環阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
US20090042864A2 (en) | 2009-02-12 |
AU2007319648A1 (en) | 2008-05-22 |
CA2664880A1 (fr) | 2008-05-22 |
TWI339205B (en) | 2011-03-21 |
WO2008060771A3 (fr) | 2008-07-24 |
CN101528706A (zh) | 2009-09-09 |
EP2084135A4 (fr) | 2010-07-28 |
US20080090809A1 (en) | 2008-04-17 |
WO2008060771A2 (fr) | 2008-05-22 |
KR20090107015A (ko) | 2009-10-12 |
EP2084135A2 (fr) | 2009-08-05 |
TW200817388A (en) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010505867A (ja) | ピラゾール化合物 | |
US8183276B2 (en) | Therapeutic agents | |
CN102459227B (zh) | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 | |
JP4693787B2 (ja) | Cb1拮抗活性を有する1,3,5−三置換4,5−ジヒドロ−1h−ピラゾール誘導体 | |
US7803799B2 (en) | Selenophene compounds | |
EA016948B1 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов | |
HRP20020496A2 (en) | Benzazole derivatives and their use as jnk modulators | |
WO2008121861A2 (fr) | Composés à base de pyrazole et de pyrrole utiles dans le traitement de troubles du métabolisme du fer | |
CN102459226A (zh) | Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂 | |
JP2021531335A (ja) | ヒストンデアセチラーゼの二環式阻害剤 | |
US7834046B2 (en) | Thiophene compounds | |
JP2006502999A (ja) | 新規置換ピラゾロ〔1,5‐a〕‐1,3,5‐トリアジン誘導体およびそれらの類似体、それを含有した医薬組成物、医薬品としてのその使用、およびその製造方法 | |
RU2600983C2 (ru) | Производные соединения пиразола | |
US7705024B2 (en) | Oxadiazole compounds | |
US8354442B2 (en) | Imidazol-4-one and imidazole-4-thione compounds | |
TW202417429A (zh) | 用於抑制yap-tead交互作用的新穎雜雙環化合物及包含其之藥學組成物 |